

Supplementary Online Content

Ross JS, Frazee SG, Garavaglia SB, et al. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. *JAMA Intern Med*. Published online July 28, 2014. doi:10.1001/jamainternmed.2014.3404

eTable 1. Beneficiary Predictors of Initiation of Ezetimibe Monotherapy or Ezetimibe Therapy Concomitant With Another Lipid Lowering Agent After Announcement of Results From the ENHANCE Trial

eTable 2. Beneficiary Predictors of Discontinuation of Ezetimibe Monotherapy or Ezetimibe Therapy Concomitant With Another Lipid Lowering Agent After Announcement of Results From the ENHANCE Trial

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Beneficiary Predictors of Initiation of Ezetimibe Monotherapy or Ezetimibe Therapy

Concomitant With Another Lipid Lowering Agent After Announcement of Results From the ENHANCE

Trial

	Ezetimibe Monotherapy (Odds Ratio, 95% CI)	Ezetimibe Therapy Concomitant with another Lipid Lowering Agent (Odds Ratio, 95% CI)
Age		
18-34 years	0.08 (0.07 - 0.10)	0.08 (0.07 - 0.09)
35-49 years	0.43 (0.40 - 0.46)	0.46 (0.44 - 0.48)
50-64 years	ref	ref
65 years of age or older	1.01 (0.96 - 1.07)	0.84 (0.81 - 0.87)
Male Sex	0.81 (0.77 - 0.84)	1.30 (1.26 - 1.35)
Concomitant Use of Other Medications for Angina/Coronary Artery Disease	2.61 (2.44 - 2.80)	3.20 (3.05 - 3.35)
Concomitant Use of Other Medications for Diabetes Mellitus	2.19 (2.07 - 2.31)	3.01 (2.89 - 3.12)
Census Division		
New England	0.65 (0.55 - 0.76)	0.62 (0.55 - 0.71)
Middle Atlantic	ref	ref
East North Central	0.87 (0.80 - 0.94)	1.06 (1.00 - 1.12)
West North Central	0.80 (0.71 - 0.90)	0.92 (0.84 - 1.01)
South Atlantic	1.03 (0.97 - 1.11)	1.07 (1.02 - 1.13)

East South Central	1.01 (0.91 - 1.13)	1.09 (1.01 - 1.19)
West South Central	0.98 (0.91 - 1.06)	1.12 (1.06 - 1.19)
Mountain	0.67 (0.59 - 0.75)	0.97 (0.89 - 1.05)
Pacific	0.74 (0.68 - 0.80)	0.85 (0.80 - 0.91)

Note: CI=Confidence Interval.

eTable 2. Beneficiary Predictors of Discontinuation of Ezetimibe Monotherapy or Ezetimibe Therapy Concomitant With Another Lipid Lowering Agent After Announcement of Results From the ENHANCE Trial

	Ezetimibe Monotherapy (Odds Ratio, 95% CI)	Ezetimibe Therapy Concomitant with another Lipid Lowering Agent (Odds Ratio, 95% CI)
Age		
18-34 years	1.60 (1.42 - 1.80)	1.57 (1.45 - 1.71)
35-49 years	1.16 (1.12 - 1.20)	1.18 (1.15 - 1.21)
50-64 years	ref	ref
65 years of age or older	0.88 (0.86 - 0.90)	1.06 (1.04 - 1.08)
Male Sex	1.21 (1.18 - 1.24)	0.92 (0.90 - 0.93)
Concomitant Use of Other Medications for Angina/Coronary Artery Disease	1.20 (1.15 - 1.24)	1.06 (1.04 - 1.09)
Concomitant Use of Other Medications for Diabetes Mellitus	1.16 (1.13 - 1.19)	1.16 (1.14 - 1.18)
Census Division		
New England	1.06 (0.98 - 1.14)	0.95 (0.90 - 1.01)
Middle Atlantic	ref	ref
East North Central	0.98 (0.94 - 1.01)	0.90 (0.87 - 0.92)
West North Central	1.11 (1.04 - 1.18)	0.93 (0.89 - 0.97)
South Atlantic	1.24 (1.20 - 1.28)	1.11 (1.08 - 1.13)

East South Central	1.10 (1.04 - 1.16)	1.06 (1.02 - 1.1)
West South Central	1.23 (1.19 - 1.28)	1.10 (1.07 - 1.14)
Mountain	1.30 (1.23 - 1.38)	1.00 (0.96 - 1.05)
Pacific	1.33 (1.28 - 1.39)	0.95 (0.92 - 0.98)

Note: CI=Confidence Interval.